ADMA CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026

ADMA Biologics faces a federal securities class action lawsuit alleging the company made false statements about its financial performance through channel stuffing schemes and undisclosed related party transactions. An investigative report revealed ADMA artificially inflated 2025 revenue growth from -3% to +20% by inducing distributors to overstock products with rebates and extended payment terms. The stock declined 29% following the report's publication on March 24, 2026. Investors who purchased securities between August 9, 2024 and March 25, 2026 may be eligible to participate, with a deadline of August 10, 2026 to seek lead plaintiff status.